Wells Fargo
ALDX icon

Wells Fargo’s Aldeyra Therapeutics ALDX Stock Holding History

Wells Fargo’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,000
Closed -$15.5K – 7169
2025
Q4 		$15.5K Buy
+3,000
New +$15.4K ﹤0.01% 5856

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Wells Fargo's ALDX Position: Q2 2026 in Review

Wells Fargo reduced its Aldeyra Therapeutics (ALDX) stake by 14% in Q2 2026, selling an estimated $47.1K and leaving 162,336 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #4862.

Wells Fargo first reported a position in ALDX in Q4 2017 and has held it in 35 quarters since. The position peaked at $2.85M in Q2 2023. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Wells Fargo held 162,336 shares of Aldeyra Therapeutics worth $346K as of Q2 2026.
  • Wells Fargo sold 27,393 Aldeyra Therapeutics shares in Q2 2026, an estimated $47.1K.
  • Aldeyra Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4862 holding.
  • Wells Fargo first reported a position in Aldeyra Therapeutics in Q4 2017 and has held it in 35 quarters since.
  • Wells Fargo's Aldeyra Therapeutics position peaked at $2.85M in Q2 2023.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.